Significance of hypoxia in uterine cervical cancer. Multicentre study

European Journal of Gynaecological Oncology

Volumn 28, Issue 5, 2007, Pages 386-388

  Markowska, J ^a   Grabowski, J P ^a   Tomaszewska, K ^a   Kojs, Z ^b   Pudelek, J ^b   Skrzypczak, M ^c   Sobotkowski, J ^d   Emerich, J ^e   Olejek, A ^f   Filas, V ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c University of Medical Sciences   (Poland)

^d Kopernik Hospital   (Poland)

^e Department of Physiotherapy   (Poland)

^f University of Medical Sciences   (Poland)

Author keywords

Cervical cancer; Hypoxia

Indexed keywords

GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; VASCULOTROPIN;

ARTICLE; BIOPSY; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; UTERINE CERVIX CANCER;

BIOLOGICAL MARKERS; CELL HYPOXIA; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; PROGNOSIS; SURVIVAL ANALYSIS; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 35148864854     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Palit V., Phillips R.M., Puri R., Shah T., Bibby M.C.: "Expression of HIF-1alpha and Glut-1 in human bladder cancer". Oncol. Rep., 2005, 14, 909.
2. Horiuchi A., Imai T., Shimizu M. et al.: "Hypoxia induced changes in the expression of VEGF, HIF-1α and cell cycle-related molecules in ovarian cancer cells". Anticancer Res., 2002, 22, 2697.
3. Jiang H., Feng Y.: "Hypoxia - inducible factor 1α (HIF-1α) correlated with tumor growth and apoptosis in ovarian cancer". Int. J. Gynecol. Cancer, 2006, 16 (suppl. 1), 405.
4. Yatabe N. et al.: "HIF-1-mediated activation of telomerase in cervical cancer cells". Oncogene, 2004, 29, 23, 3708.
5. Airley R. et al.: "Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis - free survival in advanced carcinoma of the cervix". Clin. Cancer Res., 2001, 7, 928.
6. Ziemer L.S. et al.: "Hypoxia and VEGF mRNA expression in human tumors". Neoplasia, 2001, 3, 500.
7. Mayer A. et al.: "Microregional expression of glucose transporter-1 and oxygenation status: lack of correlation in locally advanced cervical cancers". Clin. Cancer Res., 2005, 11, 2768.
8. Papanikolaou A. et al.: "Results on the treatment of uterine cervix cancer: ten years experience". Eur. J. Gynaecol. Oncol., 2006, 27, 607.
9. Narayan K., Fisher R., Bernshaw D.: "Significance of tumor volume and corpus uteri invasion in cervical cancer patients treated by radiotherapy". Int. J. Gynecol. Cancer, 2006, 16, 623.
10. Chargui R. et al.: "Prognostic factors and clinicopathologic characteristics of invasive adenocarcinoma of the uterine cervix". Am. J. Obstet Gynecol., 2006, 194, 43.
11. Vordermark D., Brown J.M.: "Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?". Strahlenther Onkol., 2003, 179, 801.
12. Burri et al.: "Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy". Int. J. Radiat. Oncol. Biol. Phys., 2003, 56, 494.
13. Chang Q. et al.: "Effect of antisense hypoxia-inducible factor 1alpha on progression, metastasis, and chemosensitivity of pancreatic cancer". Pancreas., 2006, 32, 297.
14. Sun X. et al.: "Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy". Gene Ther., 2001, 8, 638.
15. Brekken R.A., Thorpe P.E.: "VEGF-VEGF receptor complexes as markers of tumor vascular endothelium". J. Cont. Rel., 2001, 74, 173.
16. Yokoi A. et al.: "Blockade of her2/neu decreases VEGF expression but does not alter HIF-1 distribution in experimental Wilms tumor". Oncol. Rep., 2003, 10, 1271.
17. Ishikawa H. et al.: "Expression of hypoxic-inducible factor 1alpha predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma". Int. J. Radiat. Oncol. Biol. Phys., 2004, 60, 513.